Collagen type IV alpha 1 and alpha 2 chains form heterotrimers ([a1(IV)] 2 a2(IV)) that represent a fundamental basement membrane constituent. Dominant COL4A1 and COL4A2 mutations cause a multisystem disorder that is marked by clinical heterogeneity and variable expressivity and that is generally characterized by the presence of cerebrovascular disease with ocular, renal, and muscular involvement. Despite the fact that muscle pathology is reported in up to one-third of individuals with COL4A1 and COL4A2 mutations and in animal models with mutations in COL4A1 and COL4A2 orthologs, the pathophysiological mechanisms underlying COL4A1-related myopathy are unknown. In general, mutations are thought to impair [a1(IV)] 2 a2(IV) secretion. Whether pathogenesis results from intracellular retention, extracellular deficiency, or the presence of mutant proteins in basement membranes represents an important gap in knowledge and a major obstacle for developing targeted interventions. We report that Col4a1 mutant mice develop progressive neuromuscular pathology that models human disease. We demonstrate that independent muscular, neural, and vascular insults contribute to neuromyopathy and that there is mechanistic heterogeneity among tissues. Importantly, we provide evidence of a COL4A1 functional subdomain with disproportionate significance for tissue-specific pathology and demonstrate that a potential therapeutic strategy aimed at promoting [a1(IV)] 2 a2(IV) secretion can ameliorate or exacerbate myopathy in a mutation-dependent manner. These data have important translational implications for prediction of clinical outcomes based on genotype, development of mechanism-based interventions, and genetic stratification for clinical trials. Collectively, our data underscore the importance of the [a1(IV)]2a2(IV) network as a multifunctional signaling platform and show that allelic and tissue-specific mechanistic heterogeneities contribute to the variable expressivity of COL4A1 and COL4A2 mutations.
Introduction
Mutations in genes coding for collagen type IV alpha 1 (COL4A1) and alpha 2 (COL4A2) chains cause a multisystem disorder that is generally characterized by the presence of cerebrovascular disease with variable ocular, renal, and muscular involvement (MIM: 607595, 614519, 175780). [1] [2] [3] Athough most studies have focused on cerebrovascular manifestations, many aspects of the COL4A1/A2 syndrome are still emerging and remain understudied. For instance, despite the fact that muscle pathology has been reported in up to one-third of individuals with COL4A1 (MIM: 120130) and COL4A2 (MIM: 120090) mutations 1 and in animal models (mice, C. elegans, and Drosophila) with mutations in COL4A1 and COL4A2 orthologs, [4] [5] [6] [7] [8] [9] virtually nothing is known about the pathogenic mechanisms underlying COL4A1-and COL4A2-related myopathy. Mice that carry a Col4a1 splice-site mutation leading to skipping of exon 41 (Col4a1 Dex41 ) 10, 11 have transient neuromuscular-junction abnormalities during the early postnatal period 12 and develop genetically complex skeletal myopathy characterized by reduced grip strength, elevated serum creatine kinase (CK) concentrations, and increased numbers of non-peripheral nuclei (NPN). 4, 5 Col4a1 þ/Dex41 mice also have ocular dysgenesis and cerebral cortical lamination defects that are characteristic of dystroglycanopathies such as muscle-eye-brain disease and Walker-Warburg syndrome (MIM: 253280, 236670), suggesting that there might be shared pathophysiology between dystroglycan deficiency and COL4A1/A2 syndrome.
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COL4A1 and COL4A2 arose 750 million years ago with the emergence of multicellular organisms 13, 14 and produce heterotrimers ([a1(IV)] 2 a2(IV)) that are ubiquitously present during development and in nearly all mature basement membranes (BMs). 13 Despite this broad distribution, remarkable conservation, and the vast clinical spectrum of human diseases resulting from COL4A1 and COL4A2 mutations, the biological functions of [a1(IV)] 2 a2(IV) are poorly defined. The COL4A1 and COL4A2 proteins each consist of three domains; a large triple-helical domain and the flanking 7S and non-collagenous (NC1) domains at the amino and carboxy termini, respectively. Within the endoplasmic reticulum (ER), the NC1 domains initiate heterotrimer assembly, which proceeds by the progressive winding of the triple-helical domains. The pathogenicity of COL4A1 and COL4A2 mutations is generally attributed to misfolding and impaired secretion of mutant [a1(IV)] 2 a2(IV), and both intracellular retention and extracellular deficiency of [a1(IV)] 2 a2(IV) have been proposed as important pathogenic events. Using a chemical chaperone to promote [a1(IV)] 2 a2(IV) secretion reduced intracerebral hemorrhages (ICHs) in Col4a1
mice. 15, 16 However, because chemical chaperones simultaneously decrease intracellular and increase extracellular [a1(IV)] 2 a2(IV) levels, the issue of whether pathology is caused by intracellular accumulation or extracellular deficiency remains unresolved. Moreover, the possibility that the presence of mutant [a1(IV)] 2 a2(IV) in the BM could also contribute to pathology 17 has never been addressed and could have important implications for the development of targeted therapeutic interventions for individuals with COL4A1 and COL4A2 mutations. Conceptually, and in light of our recent findings, pharmacologically promoting [a1(IV)] 2 a2(IV) secretion might be beneficial for individuals with COL4A1 and COL4A2 mutations. However, if the presence of mutant [a1(IV)] 2 a2(IV) in BMs is pathogenic (via disruption of BM structure, altered cell-matrix adhesion, perturbation of downstream signaling, etc.), it is conceivable that promoting the secretion of mutant [a1(IV)] 2 a2(IV) could induce or exacerbate pathology in some tissues in a mutation-dependent manner. Thus, a fundamental question for understanding COL4A1-and COL4A2-related diseases is whether pathogenesis results from a primary intracellular or extracellular insult and, if extracellular, whether it is caused by [a1(IV)] 2 a2(IV) deficiency or by the presence of mutant proteins in the BM.
Using an allelic series of nine different murine Col4a1 and Col4a2 mutations, we identified a position-dependent effect on heterotrimer biosynthesis that correlated with ICH severity. We found that mutations closer to the carboxy terminus of the triple-helical domain caused greater intracellular accumulation and more severe ICHs. 4, 18, 19 In contrast, there was no clear correlation between secretion efficiency and myopathy severity. Instead, the mutation nearest the amino terminus of the COL4A1 protein (Col4a1 G394V ), which was among the mutations with the least intracellular accumulation and mildest ICHs, caused the most severe myopathy. 1, 2, 4 This observation supports the notion that the presence of mutant [a1(IV)] 2 a2(IV) in BMs can contribute to pathology in a tissue-specific manner and suggests that mutations affecting specific functional subdomains differentially contribute to distinct aspects of the COL4A1/A2 syndrome. In this study, we describe myopathic changes in skeletal muscles from an individual with a COL4A1 mutation. In addition, we use a combination of histological, biochemical, functional, and genetic approaches to perform a detailed characterization of COL4A1-related neuromyopathy in two Col4a1 mutant mouse strains with distinct properties. We show that Col4a1 mutant mice develop progressive skeletal myopathy that models pathology observed in individuals with COL4A1 mutations, identify a role for COL4A1 in peripheral myelination, and use conditional gene targeting to demonstrate a vascular contribution to COL4A1-related myopathy. Importantly, we identify mutation-dependent and tissue-specific responses to a potential therapeutic strategy. Understanding genotype-dependent responses to therapeutic agents is critical for effective design of clinical trials and for developing personalized interventional strategies, both of which have significant implications for individuals with COL4A1 and COL4A2 mutations.
Material and Methods

Pathologic Evaluation
Clinical and pathology reports were obtained from the University of California, San Francisco (UCSF) electronic medical records; the permission to use tissue for research was covered by the autopsy permit signed by the individual's next-of-kin. No individually identifiable data are presented in this report. Iliopsoas samples were taken during autopsy and processed for formalinfixed, paraffin-embedded sections (UCSF Clinical Histology Laboratory) and frozen sections (UCSF Laboratory for Neuromuscular Special Studies). Paraffin sections were evaluated by hematoxylin and eosin (H&E) staining, and the flash-frozen muscle was evaluated with a standard panel of muscle stains (H&E; modified trichrome; ATPase [pH 9.4]; reduced NADH-tetrazolium reductase [NADH-TR]; succinic dehydrogenase [SDH]; cytochrome oxidase [COX] ; combined COX-SDH; and dual immunohistochemistry for slow and fast myosin proteins). The slides were scanned with the Aperio whole-slide scanner, and relevant microscopic fields were extracted with Aperio ImageScope software (both from Leica Biosystems); the final images were edited with Adobe Photoshop.
Animals
All experiments were conducted in compliance with protocols approved by the Institutional Animal Care and Use Committee at UCSF (protocols AN102193 and AN159737). The two Col4a1 mutant mouse lines (Col4a1 þ/Dex41 and Col4a1 þ/G394V ) were described previously. 4, 11, 19 (Note: The Col4a1 Dex41 mutation was originally reported as Col4a1 Dex40 but has been updated to reflect subsequent genome annotations.
3 ) All mutant mice used in this study were heterozygous for a given Col4a1 mutation that was iteratively crossed to C57BL/6J (B6) mice for a minimum of 12 generations. Both male and female mice were used in all experiments and, except for an expected difference in body weight, no differences were observed between sexes, and no samples were excluded from the study. The conditional Col4a1
Flex41 mutant mouse was generated by InGenious Targeting Laboratory and previously characterized. 16, 20 The ubiquitous Actb Cre line 21 was used for validation of the conditional Col4a1 Flex41 allele. The Tek-Cre line 22 was used for induction of endothelial-cell-specific expression of the conditional Col4a1 Flex41 allele.
In Vivo Procedures
Grip-Strength Measurements Peak grip force was determined with a grip-strength meter (AMETEK TCI Division Chatillon Force Measurement Systems; re-sold by Columbus Instruments); the average from three consecutive trials was used for each animal. In brief, the grip-strength meter consists of a bar (forelimb) or a grid (forelimb and hindlimb) connected to a force meter. We tested grip strength by holding the mouse over a bar or grid until the mouse gripped the steel bars; then the mouse was pulled away from the force meter until it released the bar or grid. 
4PBA Treatment
Peripheral Nerve Conduction Velocities
Conduction action potential (CAP) recordings were performed as previously described. 25 In brief, sciatic nerves were isolated from mice under anesthesia and transferred to oxygenated recording solution (125 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM D-glucose, 1.25 mM NaH 2 PO 4 , and 25 mM NaHCO 3 ). We measured CAPs,under perfusion of recording solution, with suction electrodes at room temperature by stimulating the nerve from one end and recording at the other end. Signals were acquired with a differential AC amplifier (model 1700, AM Systems) and digitized (Axon Digidata 1440A, Molecular Devices). Constant current stimulation (50 ms) was delivered to the stimulus electrode with a stimulus isolator (ISO-Flex, A.M.P.I.). Oxygenated recording solution was perfused by gravity into the recording chamber and removed via a peristaltic pump. We measured CAPs at room temperature by delivering current via the stimulus electrode on one end of the nerve while recording the voltage response at the other end. We determined conductance velocity by dividing the length of the nerve by the latency between the start of the stimulus artifact and the peak of the CAP.
Histological and Molecular Analyses
Muscle Histopathology and Quantification of NPN Mice in the 2-month-old cohorts were challenged with exercise after grip-strength and serum-CK measurements. Each exercise session included a 2 min acclimation period followed by a 30 min exercise challenge involving a 15 downhill grade on a treadmill equipped with a shock plate (Exer 3/6, Columbus Instruments). Animals were started at 7 m/min and increased by 1 m/min each minute until a maximum of speed of 11 m/min was reached. Exercise challenges consisted of five consecutive sessions performed 3 days apart. Immediately after dissection, quadriceps, soleus, tibialis anterior, and triceps were flash frozen in liquid-nitrogen-chilled isopentane. Cryosections (10 mm) were collected from the central portions of the muscles at regular intervals (200 mm) and stained with H&E for histopathological analysis and determination of the numbers of NPN. Between 16 and 20 sections were examined per muscle, and one random field of view (203) was imaged for each section for subsequent NPN quantification. Histochemical staining for COX activity was performed according to previously published methods. 26 In brief, muscle cryosections were exposed to COX reaction media (4 mM diaminoben, zidine tetrahydrochloride, 100 mM, cytochrome C, and 20 mg/mL catalase in 0.2 M phosphate buffer [pH 7.0]) for 2 h at 37 C, dehydrated, and placed under coverslips applied with Permount.
Electron Microscope Histological Analysis of Peripheral Nerve Myelination Sciatic nerves were collected from postnatal (P6) and adult (2-to 3-month-old) mice. Adult mice were transcardially perfused with PBS, followed by 1% paraformaldehyde (PFA) prior to nerve collection. Sciatic nerves were immersion fixed in EM fixative (2% PFA and 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH ¼ 7.4) and processed for electron microscopy by the UCSF Veterans Affairs Medical Center Pathology Core. In brief, fixed sciatic nerves were cut transversely into 1.5-mm-thick blocks. Blocks were further fixed in osmium tetroxide overnight at 4 C, dehydrated through ascending ethanol washes, and embedded in resin (TAAB Laboratories). Sections (1 mm) were cut and examined by electron microscopy.
Analyses of g-Ratios g-ratios were calculated as axon area divided by the area of both the axon and the associated myelin sheath. The images of transverse sciatic nerve sections were acquired at 2,0003 magnification. Digitized and calibrated images were used for morphometric analysis with ImageJ (National Institutes of Health).
Immunoblot Analyses
Isolation, culture, and COL4A1 immunoblotting of mouse embryonic fibroblasts (MEFs) was described previously, 4 and rabbit antilaminin 1 þ 2 antibody (1:2,000, ab7463, Abcam) was used as an extracellular loading control. For sciatic-nerve samples, proteins were extracted in radioimmunoprecipitation assay (RIPA) buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% Na deoxycholic acid, and 1 mM 0.1% SDS, supplemented with a complete protease inhibitor cocktail (Pierce, USA) at 4 C. After centrifugation (13,000 rpm, 20 min at 4 C), the soluble fraction was collected. Samples were separated on a 4%-15% gradient SDS-PAGE gel under non-reducing (conditioned medium) or reducing (peripheral nerve lysates) conditions and transferred to polyvinylidene fluoride (PVDF) membranes (BioRad). Membranes were blocked for 1 h at room temperature in 5% non-fat milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) and incubated overnight at 4 C with rat monoclonal anti-myelin-basic-protein (anti-MBP) antibody (Abcam ab7349, 1:500). Mouse monoclonal anti-g-tubulin antibody (1:5000, T6557, Sigma) or polyclonal chicken anti-beta actin (1:1000, Ab13822, Abcam) was used as a loading control. After incubation with primary antibodies, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (donkey anti-rat, -rabbit, or -mouse IgG, 1:10 000, Jackson ImmunoResearch) diluted in 5% non-fat milk in TBS-T for 1 h at room temperature. Immunoreactivity was visualized by chemiluminescence (Pierce ECL Chemiluminescent Substrate, Thermo Scientific). Densitometric analysis was performed on low-exposure images with ImageJ (National Institutes of Health). Immunolabeling Myelin basic protein (MBP) immunolabeling was performed on 20 mm cryosections that were fixed in 4% PFA in PBS, blocked for 1 h at room temperature in blocking buffer (PBS containing 10% normal donkey serum and 0.1% Triton X-100), and incubated overnight at 4 C with or rat anti-MBP (Abcam, ab7349, 1:500) antibodies in blocking buffer. Immunolabeling was visualized with AlexaFluor-594-conjugated secondary antibodies (raised in donkey, 1:500, Invitrogen-Molecular Probes) in blocking buffer. Dual myosin-heavy-chain (MHC) immunolabeling for myofiber typing was performed on 20 mm cryosections from soleus muscles as described previously. 27 In brief, sections were blocked for 1 h at Figures 1B-1B  00 ). Although the initial report raised the possibility of mitochondrial defects, 28 we found that COX-deficient fibers were also negative for succinate dehydrogenase (SDH) activity and were found exclusively in the affected areas, consistent with a nonspecific pattern of muscle-fiber injury ( Figures 1C-1C  00 ). Histological analyses of skeletal muscles from Col4a1 mutant mice revealed a similar spectrum of myopathic changes; these included NPN, variable fiber size, clusters of necrotic and regenerating myofibers, endomysial fibrosis, and secondary infiltration of inflammatory cells (Figures 2A-2F ). Consistent with observations in the human muscle biopsy, Col4a1 mutant mice showed no abnormalities in the distribution of type I and type II fibers ( Figures 2G-2I) ; furthermore, COX staining did not reveal evidence of any mitochondrial defects ( Figures 2J-2L) . Notably, myopathic lesions observed in Col4a1 mutant skeletal muscles also had a patchy distribution (often showing perifascicular prominence) and appeared to represent lesions at different stages of the same disease process.
General and Progressive Skeletal Myopathy in Col4a1-
Mutant Mice
To better define pathology caused by Col4a1 mutations, we characterized myopathy in two different Col4a1 mutant mouse strains-Col4a1 Dex41 and Col4a1
G394V
. We selected these strains from an allelic series of Col4a1 mutant mice because they showed the most severe myopathy according to NPN quantification in quadriceps while having different effects on [a1(IV)] 2 a2(IV) secretion. 4 Both mutations occur in the COL4A1 triple-helical domain; the Col4a1 Dex41 mutation is a splice acceptor mutation leading to skipping of exon 41 (amino acids 1169-1185), whereas Col4a1 G394V is an archetypal glycine missense mutation. Notably, the Col4a1 Dex41 mutation significantly impairs [a1(IV)] 2 a2(IV) secretion, whereas the Col4a1 G394V mutation does not 4 ( Figure S1 ). Mutant mice had significantly increased numbers of NPN in all muscle types examined (Figures 3A-3D), and both strains had significantly elevated serum CK concentrations ( Figure 3E ). In addition, increases in NPN numbers and CK concentrations were more pronounced with age, suggesting that myopathy is progressive. To test whether the histological and biochemical changes reflected impaired myo-mechanical properties, we analyzed isolated extensor digitorum longus and found significantly reduced maximal tetanic tension in Col4a1 þ/Dex41 and Col4a1 þ/G394V mice, and there were significantly lower maximal twitch tensions in Col4a1 þ/G394V mice than in
Together with measures of histological and biochemical outcomes, these observations support the conclusion that myopathy is more severe in Col4a1 þ/G394V than in Col4a1 þ/Dex41 mice. In contrast, while both Col4a1
and Col4a1 þ/G394V mice had reduced grip forces compared to Col4a1 þ/þ littermates ( Figures 4D-4F ), grip strength was significantly lower in Col4a1 þ/Dex41 compared to Col4a1 þ/G394V mice at 2 months. Because grip strength reflects the functional integration of multiple systems, these data suggest that other tissues that are differentially affected by the two mutations might be contributing to COL4A1-related myopathy. Collectively, these findings demonstrate that Col4a1 mutations cause generalized and progressive skeletal myopathy that is modulated by allelic heterogeneity and potentially involves contributions of extra-muscular tissues.
Col4a1-Mutant Mice Have Hypomyelination of Peripheral Nerves COL4A1 was recently identified as a ligand for the adhesion G-protein-coupled receptor GPR126, which is required for Schwann cell maturation. [29] [30] [31] To begin addressing the potential contribution of extra-muscular tissues to COL4A1-related myopathy, we tested whether Col4a1-mutant mice have peripheral nerve abnormalities. We first assessed peripheral nerve myelination by using area-based g-ratios to quantify myelin thickness on electron micrographs of sciatic nerves from 2-to-3-month old mice; we found a small but significant decrease in myelination in Col4a1 þ/Dex41 mice ( Figure S2 ). We also detected a significant reduction in myelin thickness in sciatic nerves from Col4a1 þ/Dex41 mice at postnatal day 6 (P6) (Figures 5A-5C ). Notably, at this age, we observed abnormally large bundles of unmyelinated axons with irregular morphology, mixed-caliber axons, and abnormally thin Schwann cell processes between individual axons, suggestive of impaired radial sorting ( Figures 5A, 5B , and 5D). In agreement with these observations, immunoblot analyses and immunolabeling revealed reduced MBP levels in nerves from Col4a1 þ/Dex41 mice during the early postnatal period ( Figures 5E-5G ). Finally, we detected significantly reduced conduction velocities in sciatic nerves from P7 Col4a1 þ/Dex41 mice ( Figure 5H ). Collectively, these ultrastructural, molecular, and physiological data identify developmental peripheral neuropathy in Col4a1 littermates had significantly increased numbers of NPN and reduced grip strength; these findings were comparable to those observed in Col4a1 þ/Dex41 mice ( Figures S3A-S3D ). and homozygous-conditional mutant mice had reduced grip strength ( Figure 6D ). To test whether a primary vascular insult might also contribute to peripheral hypomyelination, we evaluated MBP levels in sciatic nerves from P7 mice that conditionally express mutant COL4A1 in vascular endothelial cells, and we found that Tek Cre ;
Col4a1
Flex41/Flex41 mice had slightly reduced MBP levels that did not reach statistical significance ( Figures 6E and  6F ). Together, these results conclusively establish that vascular defects contribute to myopathy in Col4a1 mutant mice. mice. 15, 16 To build on our recent findings and determine whether promoting [a1(IV)] 2 a2(IV) secretion could provide long-term and general protective effects for COL4A1-related myopathy, we provided Col4a1
and Col4a1 þ/G394V mice with 4PBA from E9.5 to the age of 2 or 8 months, when we quantified NPN and grip strength. Although 4PBA had no effect on Col4a1 þ/þ mice, it significantly reduced NPN numbers and improved grip strength in Col4a1 þ/Dex41 mice at both 2 and 8 months of age ( Figures   7A-7D and Figures S4A-S4D, respectively) . In striking contrast, 4PBA treatment led to an increase in NPN numbers in all muscle groups examined in Col4a1
mice, although there was no effect on grip force ( Figures  7E-7K ). These data support a model whereby the presence of mutant proteins in BMs can be pathogenic. Collectively, these findings identify a contrasting response to a potential therapeutic strategy whereby pharmacological promotion of [a1(IV)] 2 a2(IV) secretion can ameliorate or exacerbate a particular phenotype in a mutation-dependent manner.
Dichotomous Intra-Allelic Responses to a Chemical Chaperone Reveal Tissue-Specific Mechanistic Heterogeneity
In addition to reducing ICH and myopathy severities in Col4a1 þ/Dex41 mice, 4PBA prevented peripheral nerve hypomyelination, as illustrated by increased MBP levels in P7 sciatic nerves ( Figures 8A and 8C ). To test whether the exacerbation of myopathy observed in 4PBA-treated Col4a1 þ/G394V mice resulted from an inherent property of this mutation that extends to other phenotypes, we compared peripheral nerve myelination and ICH severity in Col4a1 þ/G394V mice with and without 4PBA treatment.
Similar to what we observed in Col4a1 þ/Dex41 mice, Col4a1 þ/G394V mice had reduced sciatic nerve MBP levels that were normalized by 4PBA administration ( Figures  8B-8C) , and Col4a1 þ/G394V mice had nearly undetectable ICHs, which were not exacerbated by 4PBA treatment ( Figure 8D-8F) . Thus, pharmacologically promoting [a1(IV)] 2 a2(IV) secretion had beneficial effects for all pathologies tested in Col4a1 þ/Dex41 mice, but had contrasting and tissue-specific effects in Col4a1 þ/G394V mice (where it exacerbated myopathy but ameliorated peripheral neuropathy and had no effect on ICHs).
Discussion
Col4a1 and Col4a2 mutant mice recapitulate the pathophysiological manifestations observed in individuals with COL4A1 and COL4A2 mutations. The novel neuromuscular phenotypes described here expand the clinical spectrum of the COL4A1/A2 syndrome and provide significant biological insight into the underlying pathogenesis. Using a combination of histological, biochemical, functional, and genetic approaches, we show that tissue-specific allelic and mechanistic heterogeneities contribute to the neuromuscular manifestations caused by Col4a1 mutations. Together, these findings underscore the importance of the [a1(IV)] 2 a2(IV) network as a multifunctional signaling platform that can elicit independent differential tissue-specific responses; these findings have broad implications for understanding and treatment of the COL4A1/A2 syndrome.
Myopathy is not well characterized in individuals with COL4A1 and COL4A2 mutations; only a few studies report nonspecific and widespread myopathic changes in biopsies. 5, 33 Here, we performed a histopathological analysis of skeletal muscle samples from an individual previously described as having a de novo COL4A1 mutation, c.2317G>A (p.Gly773Arg), 28 and we identify myopathy presenting as scattered lesions characterized by the presence of fibers in varying stages of necrosis and regeneration, endomysial fibrosis, and focal fatty infiltration. The subject also had cataracts, hypertrophic cardiomyopathy, and ischemic cerebrovascular pathology; 28 although metabolic myopathy was initially suggested, we found no evidence for a significant role of mitochondrial defects in the underlying disease process. 28 Out of 130 published COL4A1 mutations, the p.Gly775Arg mutation was described in four independent reports. 1, 28, [34] [35] [36] The clinical presentation of seven affected individuals from four unrelated families described in these studies was highly variable (even within a family) and included ICH, white-matter abnormalities, cataracts, ocular dysgenesis, muscle cramps, and serum CK concentration elevations. We have previously demonstrated that genetic context and environmental interactions contribute to variable expressivity of Col4a1 mutations in mice, 2, 5, 10, 16, 37 and these clinical observations underscore the variable expressivity of COL4A1 mutations among individuals with the same amino acid change. We previously showed that allelic heterogeneity modulates the penetrance and severity of COL4A1-related pathologies, including ICHs and myopathy. 4, 16 The relative severity of myopathy in Col4a1 þ/G394V mice and its exacerbation after 4PBA treatment suggest that this mutation directly disrupts a subdomain important for skeletal muscle function and implies the existence of subclasses of mutations with disproportionate contributions to tissue-specific pathologies. Notably, a cluster of COL4A1 mutations is reported in a subset of individuals from six families who have a clinical diagnosis of HANAC syndrome (hereditary angiopathy with nephropathy, aneurysms, and muscle cramps, 17,38-40 MIM: 611773) and who typically present with muscle pathology. Although muscle cramps and serum CK elevation are characteristic manifestations observed in individuals with HANAC syndrome, cerebrovascular disease is usually clinically silent. 17, [38] [39] [40] The mutations ascribed to HANAC syndrome (p.Gly498Asp, p.Gly498Val, p.Gly510Arg, p.Gly519Arg, p.Gly525Leu, and p.Gly528Asp) are spread over 30 amino acids in an area of the triple-helical domain containing putative interaction sites for multiple ECM-associated proteins and cell-surface receptors. However, none of the affected amino acids occur in clearly defined consensus binding sites. 41 Thus, it remains unresolved whether HANAC syndrome represents a distinct clinical or mechanistic entity whereby mutations directly perturb important functional subdomains 42 or falls within the broad spectrum of the COL4A1/A2 syndrome. A possible ascertainment bias could contribute to apparent genotypephenotype correlations whereby subtle phenotypes (elevated CK or albuminuria) become more likely to be detected in the absence of life-threatening cerebrovascular disease (as predicted for individuals with mutations nearer the amino terminus of the protein). Genetic alterations leading to disruption of the molecular networks linking the BM and myofiber cytoskeleton are well-established causes of congenital muscular dystrophies that often involve peripheral neuropathy. 43 Deficiency of the BM protein, laminin alpha 2 (LAMA2), or its cell-surface receptors, a7b1 integrin and the dystroglycan complex, cause congenital muscular dystrophy with peripheral neuropathy (MIM: 607855, 613204). [44] [45] [46] [47] [48] Although myopathy caused by COL4A1 mutations is significantly milder than that observed in LAMA2-related myopathy, it is important to consider that COL4A1 mutations are dominant and that LAMA2-related myopathy is typically only observed when homozygous or compound heterozygous mutations lead to near-complete absence of the protein.
Furthermore, the biological importance of [a1(IV)] 2 a2(IV) in muscle homeostasis might be masked by co-morbidity with other serious or fatal pathologies. The proximity of the Col4a1 G394V mutation to a putative integrin binding site (GFOGERGEKG/V) makes it tempting to speculate that this mutation locally disrupts the triple helix and impairs integrin binding. 41 However, Col4a1 G394V is adjacent to a consensus integrin a1b1/a2b1 binding motif, and a7b1 is the predominant integrin expressed by muscle fibers. [49] [50] [51] Regardless of the function of the putative integrin-binding domain, elucidating the molecular mechanisms underlying COL4A1-related neuromyopathy might also have therapeutic implications for individuals with LAMA2 (MIM: 156225) mutations. For example, augmenting LAMA2-mediated linkages might ameliorate myopathy resulting from COL4A1 and COL4A2 mutations; reciprocally, the molecular pathways underlying COL4A1-related myopathy could represent alternative therapeutic targets for individuals with LAMA2 mutations. Identification of peripheral nerve hypomyelination in Col4a1 mutant mice further reinforces the similarities between neuromuscular pathology caused by COL4A1 and LAMA2 mutations. In this case, COL4A1 and LAMA2 are extracellular ligands for the same adhesion G-protein-coupled receptor, GPR126, which is required for Schwann cell maturation and peripheral myelination. [29] [30] [31] 52 The COL4A1 globular NC1 domain mediates the GPR126 interaction, which is consistent with mechanistically distinct functions for COL4A1 in skeletal muscles and peripheral nerves. Interestingly, type III collagen is an extracellular ligand for GPR56, 53 and perturbations cause cortical lamination defects that can also occur in the spectrum of phenotypes included in COL4A1/A2 syndrome. 5 Thus, it is possible that the COL4A1/A2 syndrome includes other aspects (including ocular dysgenesis, lamination defects, and white-matter abnormalities) that could be attributable to roles for COL4A1 and COL4A2 as ligands for diverse GPCRs. These observations support the idea that different COL4A1 functional subdomains mediate tissue-specific functions and are consistent with mechanistic heterogeneity in COL4A1-related myopathy and peripheral neuropathy. A primary vascular etiology for COL4A1-related skeletal myopathy was suggested previously on the basis of muscle histopathology in Col4a1 G498V mutant mice, where ER stress was detected in vascular endothelial cells. 6 However, it remains to be determined whether ER stress is indeed causative and whether myopathy in Col4a1
G498V
-mutant mice (a model for HANAC) primarily results from an intracellular vascular endothelial insult, as proposed, 6 or from an extracellular insult similar to that resulting from the Col4a1 G394V mutation presented here. Thus, determining whether myopathy is exacerbated or ameliorated in Col4a1 þ/G498V mice in response to 4PBA will be important for understanding whether HANAC is clinically and mechanistically distinct or simply part of the broad clinical spectrum of the general COL4A1/A2 syndrome. Regardless, selective expression of mutant COL4A1 Dex41 in vascular endothelial cells mimics many aspects of the disease caused by ubiquitous expression of the mutant protein, clearly demonstrating that there is a vascular contribution to COL4A1-related myopathy. Furthermore, the discordant consequences of the Col4a1 G394V mutation on the severity of ICHs and myopathy and the contrasting tissue-specific responses to 4PBA treatment suggest that the molecular mechanisms underlying vascular and skeletal muscle pathologies are distinct. Collectively, the findings presented in this study suggest that independent and integrated muscular, neural, and vascular insults contribute to the overall neuromuscular phenotype caused by Col4a1 mutations but that the underlying molecular mechanisms differ between tissues. Together with our previous findings from an allelic series of Col4a1 and Col4a2 mutant mice, the current study offers a general model to explain the pathogenicity of COL4A1 and COL4A2 mutations; in this model the proximal insult for most mutations is a dominant-negative impairment of [a1(IV)] 2 a2(IV) secretion that functions as a graded series of hypomorphs for which the severity depends on their positions along the protein's amino-carboxy axis. ICHs appear to be a representative phenotype for this model and, as predicted, promoting [a1(IV)] 2 a2(IV) secretion suppresses ICHs. 15, 16 Given that the GPR126 interaction is mediated by the NC1 domain, and in light of our current findings, we predict that peripheral nerve hypomyelination will follow the same genotype-phenotype profile followed by ICH severity. While the mechanism(s) underlying vascular pathology remain(s) unknown, the pathogenesis of peripheral neuropathy almost certainly involves extracellular deficiency rather than toxic cell-intrinsic accumulation of misfolded [a1(IV)] 2 a2(IV) in Schwann cell precursors. In contrast, the exacerbation of myopathy in Col4a1 þ/G394V mice treated with 4PBA indicates a qualitative, not quantitative, extracellular insult. Thus, neuromyopathy in Col4a1 mutant mice appears to integrate at least three distinct pathogenic mechanisms in three different tissues.
The multi-functionality of the type IV collagen network presents a conceptual challenge for classifying mutations. Because COL4A1 has diverse extracellular roles, the qualitative or quantitative properties of a given mutation can vary in a tissue-specific manner. Thus, a specific mutation can simultaneously have cell-autonomous dominantnegative effects on [a1(IV)] 2 a2(IV) secretion and also have quantitative loss-of-function effects in one tissue and qualitative gain-of-function effects in another; these effects could be cell autonomous or non-autonomous. The dichotomous behavior of the Col4a1 G394V mutation across different tissues is a proof of concept for this important paradigm, and the classification of COL4A1 and COL4A2 mutations might become increasingly multi-dimensional as additional biological roles for [a1(IV)] 2 a2(IV) are identified. Given that mutations nearer the NC1 domain tend to cause more severe [a1(IV)] 2 a2(IV) secretion impairments, there might be an ascertainment bias toward identification of functional subdomains that are closer to the amino-terminal end of the protein in heterotrimers that reach the BM. Similarly, mutations with potential extracellular qualitative effects that occur near the NC1 domain might be ''invisible'' without artificially enhancing secretion of the mutant [a1(IV)] 2 a2(IV). Evaluating tissue-specific responses to 4PBA treatment across multiple mutations could be a useful tool for the mechanistic classification of mutations. Therapeutically promoting [a1(IV)] 2 a2(IV) secretion might end up being beneficial for the majority of mutations; however, this approach could exacerbate or induce tissue-specific pathologies for mutations occurring in specific functional subdomains. We predict that the eventual construction of a high-resolution map of functional subdomains for the type IV collagen network will guide the genetic stratification of human subjects into clinical and mechanistic subgroups that will distinguish those who are likely to benefit from promoting secretion from those who might require additional or alternative interventions that target distal extracellular insults. Finally, rather than assigning pathognomonic acronyms to clinical features, we propose a nosological classification of the COL4A1/ A2 syndrome into clinically and mechanistically related disease subtypes as described for osteogenesis imperfecta (MIM: 166200, 166210, 259420, 166200, 613982) caused by mutations in COL1A1 (MIM: 120150) and COL1A2 (MIM: 120160) (e.g., COL4A1/A2 syndrome type I, type II, type III, etc.).
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